Jonah Larkins-Ford
Overview
Explore the profile of Jonah Larkins-Ford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1013
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van N, Degefu Y, Leus P, Larkins-Ford J, Klickstein J, Maurer F, et al.
Antimicrob Agents Chemother
. 2023 Jun;
67(7):e0009023.
PMID: 37278639
Mycobacterium abscessus infections are difficult to treat and are often considered untreatable without tissue resection. Due to the intrinsic drug-resistant nature of the bacteria, combination therapy of three or more...
2.
Larkins-Ford J, Aldridge B
Expert Opin Drug Discov
. 2022 Dec;
18(1):83-97.
PMID: 36538813
Introduction: Tuberculosis requires lengthy multi-drug therapy. occupies different tissue compartments during infection, making drug access and susceptibility patterns variable. Antibiotic combinations are needed to ensure each compartment of infection is...
3.
Larkins-Ford J, Degefu Y, Van N, Sokolov A, Aldridge B
Cell Rep Med
. 2022 Sep;
3(9):100737.
PMID: 36084643
A challenge in tuberculosis treatment regimen design is the necessity to combine three or more antibiotics. We narrow the prohibitively large search space by breaking down high-order drug combinations into...
4.
Govindan J, Jayamani E, Zhang X, Breen P, Larkins-Ford J, Mylonakis E, et al.
Nat Cell Biol
. 2022 Apr;
24(6):1005-1007.
PMID: 35411089
No abstract available.
5.
Larkins-Ford J, Greenstein T, Van N, Degefu Y, Olson M, Sokolov A, et al.
Cell Syst
. 2021 Sep;
12(11):1046-1063.e7.
PMID: 34469743
Lengthy multidrug chemotherapy is required to achieve a durable cure in tuberculosis. However, we lack well-validated, high-throughput in vitro models that predict animal outcomes. Here, we provide an extensible approach...
6.
Smith 2nd T, Pullen K, Olson M, McNellis M, Richardson I, Hu S, et al.
Proc Natl Acad Sci U S A
. 2020 Jul;
117(31):18744-18753.
PMID: 32680963
Morphological profiling is a method to classify target pathways of antibacterials based on how bacteria respond to treatment through changes to cellular shape and spatial organization. Here we utilized the...
7.
Ma S, Jaipalli S, Larkins-Ford J, Lohmiller J, Aldridge B, Sherman D, et al.
mBio
. 2019 Nov;
10(6).
PMID: 31719182
The rapid spread of multidrug-resistant strains has created a pressing need for new drug regimens to treat tuberculosis (TB), which kills 1.8 million people each year. Identifying new regimens has...
8.
Cokol M, Kuru N, Bicak E, Larkins-Ford J, Aldridge B
Sci Adv
. 2017 Oct;
3(10):e1701881.
PMID: 29026882
Combinations of three or more drugs are used to treat many diseases, including tuberculosis. Thus, it is important to understand how synergistic or antagonistic drug interactions affect the efficacy of...
9.
Khaperskyy D, Schmaling S, Larkins-Ford J, McCormick C, Gaglia M
PLoS Pathog
. 2016 Feb;
12(2):e1005427.
PMID: 26849127
Influenza A viruses (IAVs) inhibit host gene expression by a process known as host shutoff. Host shutoff limits host innate immune responses and may also redirect the translation apparatus to...
10.
Dolla N, Chen C, Larkins-Ford J, Rajamuthiah R, Jagadeesan S, Conery A, et al.
Aust J Chem
. 2016 Jan;
67:1471-1480.
PMID: 26806960
Berberine-INF55 hybrids are a promising class of antibacterials that combine berberine and the NorA multidrug resistance pump inhibitor INF55 (5-nitro-2-phenylindole) together in one molecule via a chemically stable linkage. Previous...